DRR168606
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.540
- G2M_CHECKPOINT+0.530
- MYC_TARGETS_V2+0.470
- IL6_JAK_STAT3_SIGNALING+0.440
- MYC_TARGETS_V1+0.440
- ALLOGRAFT_REJECTION+0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.380
- INFLAMMATORY_RESPONSE+0.370
- MITOTIC_SPINDLE+0.360
- TNFA_SIGNALING_VIA_NFKB+0.340
Top 10 suppressed
- NOTCH_SIGNALING-0.240
- PANCREAS_BETA_CELLS-0.240
- P53_PATHWAY-0.200
- WNT_BETA_CATENIN_SIGNALING-0.190
- APICAL_SURFACE-0.150
- MYOGENESIS-0.130
- BILE_ACID_METABOLISM-0.110
- PEROXISOME-0.090
- DNA_REPAIR-0.060
- ANGIOGENESIS-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 6e639239-cdae-4412-880f-ef813a956ff7 | — | — | 0.846 |
| 2 | SRR26320090 | — | — | 0.833 |
| 3 | DRR168600 | — | — | 0.828 |
| 4 | c96595aa-4604-4ec6-8b54-c97b3543777e | — | — | 0.819 |
| 5 | DRR168585 | — | — | 0.814 |
| 6 | 27dfc12e-4ed1-4d98-b6af-d4e9cbb96779 | — | — | 0.813 |
| 7 | R398 | — | — | 0.811 |
| 8 | SRR13311163 | — | — | 0.810 |
| 9 | 20130321.TNBC | — | C | 0.804 |
| 10 | TCGA-BH-A0GY-01A-11R-A056-07 | — | C | 0.804 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.360 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.340 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.320 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.240 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.240 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.210 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |